Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Apeiron Therapeutics (Hong Kong) Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 2 examiners and 2 art units, showing separate examination channels within the portfolio.
HAVLIN, ROBERT H is the busiest examiner, with 1 pending matter. The remaining workload is therefore outside that examiner’s docket, making matter-specific review important when coordinating responses across the biotechnology portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | HAVLIN, ROBERT H | — |
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | — | Pending | Feb 13, 2026 |
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | MOSELEY II, NELSON B | 1642 | §103DP | Non-Final OA | — | Pending | Feb 13, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialApeiron Therapeutics (Hong Kong) Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert H Havlin has the most, with 1 of Apeiron Therapeutics (Hong Kong) Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
